Foci Pharmaceutical(002644)2025-04-25 12:55Financial Performance - The company's operating revenue for 2024 was ¥980,225,387.73, a decrease of 15.73% compared to ¥1,163,134,313.96 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥60,069,813.05, down 10.60% from ¥67,189,706.97 in 2023[17]. - The net cash flow from operating activities decreased by 40.68% to ¥38,984,923.46 in 2024 from ¥65,714,299.86 in 2023[17]. - Basic earnings per share for 2024 were ¥0.1176, a decline of 10.64% from ¥0.1316 in 2023[17]. - Total assets at the end of 2024 were ¥2,469,785,308.07, a decrease of 2.31% from ¥2,528,102,214.36 at the end of 2023[17]. - The net assets attributable to shareholders increased by 2.55% to ¥1,789,888,294.75 at the end of 2024 from ¥1,745,370,807.77 at the end of 2023[17]. - The company reported a total of 467 drug approval numbers, with 10 exclusive products in its portfolio[31]. - The overall performance of the pharmaceutical manufacturing industry in 2024 is expected to remain flat compared to 2023, with a 1.1% decline in total profits[26]. - The company achieved operating revenue of 98,022.54 million yuan in 2024, a decrease of 15.73% compared to the previous year[37]. - The total profit amounted to 6,913.95 million yuan, down 15.31% year-on-year, while the net profit attributable to shareholders was 6,006.98 million yuan, a decrease of 10.60%[37]. Market and Product Development - The company is positioned in the traditional Chinese medicine sector, benefiting from government support and increasing health awareness among the population[27]. - In 2024, various national policies were introduced to promote the development of traditional Chinese medicine, emphasizing innovation and quality improvement[28][29]. - The company launched over 30 health tea products, including "Xiao Yao Soup" and "Qing Qing Peach Blossom Drink"[37]. - The company developed 14 new patents, with 3 invention patents and 1 design patent approved, and received a second-class award for patents in Gansu Province[39]. - The company is conducting research on three exclusive traditional Chinese medicine products, with the first phase completed and the second phase underway[66]. - Five health food products have been developed under the concept of food-medicine homology, contributing to the company's health industry expansion[66]. - The company aims to leverage Gansu's local medicinal resources to enhance its traditional Chinese medicine health industry development[66]. Operational Efficiency and Cost Management - The company has reduced water, electricity, and gas consumption by 7.0%, 2.8%, and 9.1% respectively, saving approximately 1.41 million yuan[40]. - The company’s inventory increased by 37.18% to ¥197,736,309.13, attributed to adjustments in production structure and planning[58]. - Research and development expenses amounted to ¥29,284,084.57, reflecting a decrease of 5.31% from the previous year[64]. - The company’s total operating costs for the pharmaceutical sector were ¥680,513,278, a decrease from ¥801,838,651 in the previous year[60]. - Sales expenses decreased by 24.51% to ¥116,044,604.78, while management expenses fell by 18.19% to ¥68,957,995.30[64]. Governance and Management - The company has established a value management system to enhance investment value and protect stakeholders' rights, approved by the board on April 25, 2025[97]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although details on its disclosure were not provided[98]. - The company governance structure complies with relevant laws and regulations, ensuring proper operation and protection of shareholder rights[100]. - The board of directors was re-elected on August 14, 2024, following a fair and transparent selection process[101]. - The supervisory board was also re-elected on August 14, 2024, maintaining compliance with legal requirements[101]. - The company operates independently from its controlling shareholder in terms of business, personnel, assets, and finance, ensuring a complete and autonomous operational system[104]. - The company has established an independent financial department with its own accounting system, ensuring independent financial decision-making[105]. Shareholder Engagement and Profit Distribution - The company plans to distribute a cash dividend of ¥0.12 per 10 shares, based on a total of 510,657,000 shares[5]. - The profit distribution policy for the reporting period was maintained without changes, and the company has a three-year shareholder return plan for 2024-2026[133]. - The company reported a total of 60,069,813.05 yuan in distributable profits for the reporting period[135]. - The cash dividend distribution accounted for 100% of the total profit distribution amount[135]. - The company distributed a total of 15.32 million CNY in cash dividends during the reporting period, sharing development dividends with all shareholders[149]. Social Responsibility and Environmental Management - The company actively engaged in social responsibility by donating pharmaceuticals worth 602,000 CNY to the Gansu Province Veterans Care Foundation and the Gansu Province Women and Children Development Foundation[152]. - The company employed nearly 100 local farmers for medicinal herb processing, contributing to local employment and income generation[154]. - The company established a comprehensive environmental management system, achieving ISO 14001:2015 and ISO 45001:2018 certifications[146]. - The company has not faced any significant environmental pollution incidents or administrative penalties related to environmental issues during the reporting period[147]. - The company has developed an emergency plan for environmental risk events to minimize the occurrence of such incidents[146]. Future Outlook and Strategic Plans - The company aims to enhance its market presence in the Northwest and expand into the South China and international markets, focusing on a dual-driven model of traditional Chinese medicine and health industry[81]. - The 2025 operational plan emphasizes high-quality development, innovation, and digitalization, aligning with national strategic directives[82]. - The company targets five billion-yuan markets and four ten-million-yuan markets, aiming to boost sales through product diversification and market expansion[83]. - The company plans to strengthen brand management and expand its influence through cultural tourism and various advertising channels[83]. - The company is committed to developing new health products and enhancing existing ones, with ongoing research on two health products and four major varieties[88].